News Headlines Article

Johnson & Johnson Profit Beats Estimates on New Drug Sales
San Francisco Chronicle

Johnson & Johnson, the world’s biggest maker of health-care products, reported third-quarter profit that beat analysts’ estimates as newer drugs continue to propel the company to faster growth than competitors. J&J raised its full-year forecast.

Earnings excluding one-time items of $1.36 a share beat the $1.32 average of 17 analysts’ estimates compiled by Bloomberg. Profit may be $5.44 to $5.49 a share for 2013, the New Brunswick, New Jersey-based company said today in a statement.

Commands